Maynard Um
-
-
-
-
-
-
-
Jaguar Health MVID trial moves to extension phase ahead of 2027 NDA
-
-
-
-
-
-
-
Jaguar Health (JAGX) Tops Q2 EPS by 3647c
-
-
-
-
-
-
-
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
-
-
-
-
-
-
-
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
-
-
-
-
-
-
-
Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases
-
-
-
-
-
-
-
Jaguar Health (JAGX) Misses Q1 EPS by 1360c
-
-
-
-
-
-
-
Jaguar Health discusses FDA breakthrough therapy designation for rare disease treatment
-
457,178 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

